PTSM: Pharmaceutical Technology Sourcing and Management, Oct 8, 2008 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PTSM: Pharmaceutical Technology Sourcing and Management, Oct 8, 2008
Outsourcing Outlook
Big Deals
By Jim Miller
Summer deals struck by Novartis and Lilly point to an evolution in contract services.
Global Feature
REACH's Impact on the Pharmaceutical Industry
By Carole Garcia
The pharmaceutical industry faces compliance with the REACH regulation, the European Union's regulation on chemicals and their safe use. Fully understanding the requirements, achieving compliance, and developing strategies for working with suppliers are key for avoiding interruption of the supply chain.
APIs
Ricerca Biosciences in Expansion Mode
By Patricia Van Arnum
Buoyed by increased demand for pharmaceutical outsourcing services, Ricerca Biosciences proceeds with an expansion plan.
Ingredients and Materials
Sourcing and Management Launches Community of Experts Panel
By Patricia Van Arnum
Leading professionals join the community of experts panel of Sourcing and Management.
News From CPhI
Contract Manufacturers and Pharmaceutical Ingredient Suppliers Gather for CPhI
By Patricia Van Arnum
SAFC, Regis Technologies, Carbogen Amcis, Cambridge Major Laboratories, and AMRI are among the companies at CPhI Worldwide in Frankfurt this week that are moving forward with expansions.
Ionic Liquids in the Chemical Synthesis of Pharmaceuticals
By Matthias Maase
Ionic liquids provide an alternative to certain solvents in select reactions used to synthesize intermediates and active pharmaceutical ingredients.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Click here